简体
简体中文
繁體中文

Cytosorbents CTSO

等待开盘 05-18 09:30:00 美东时间

0.4976

-0.044

-8.16%

华盛通华盛通
立即下载
  • 最 高0.55
  • 今 开0.5268
  • 成交量 19.00万股
  • 最 低 0.4916
  • 昨 收 0.5418
  • 总市值 3124.67万
  • 52周最高 1.39
  • 市盈率 --
  • 换手率 0.30%
  • 52周最低 0.4916
  • 委 比 99.29%
  • 总股本 6279.47万
  • 历史最高 15.24
  • 量 比 1.74
  • 振 幅 10.78%
  • 历史最低 0.09
  • 每 手 1
  • 风险率 0.18%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Transcript: CytoSorbents Q1 2026 Earnings Conference Call

    CytoSorbents (NASDAQ:CTSO) reported first-quarter financial results on Wednesda...

    05-14 05:36

  • CytoSorbents Q1 Adj. EPS $(0.05) Beats $(0.06) Estimate, Sales $8.864M Miss $9.363M Estimate

    CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 0 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same

    05-14 04:01

  • Earnings Scheduled For May 13, 2026

    Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...

    05-13 19:11

  • CytoSorbents Receives Nasdaq Extension to Regain Compliance

    An update from Cytosorbents ( ($CTSO) ) is now available. On April 1, 2026, Cyt...

    04-02 19:42

  • CytoSorbents wins Nasdaq extension to regain $1 minimum bid compliance

    CytoSorbents wins Nasdaq extension to regain $1 minimum bid compliance CytoSorbents received a Nasdaq notice granting a 180-day extension to regain compliance with minimum $1 bid price listing rule. New compliance deadline set for Sept. 28, 2026. Compliance can be restored if shares close at or abov

    04-02 19:03

  • 电话会总结 | Cytosorbents(CTSO)2025财年Q4业绩电话会核心要点

    <span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>&#8226; 根据Cytosorbents业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 2025年全年总收入3,710万美元,同比增长4%,创下核心产品销售记录 - Q4收入920万美元,同比增长1%,但按固定汇率计算下降8% - 德国以外直接国际销售860万美元,同比增长13% - 经销商销售1,650万美元,同比增长11.4% - 德国销售1,180万美元,同比下降10% **盈利能力:** - 全年毛利率71%,Q4毛利率74%,显示制造效率提升 - 全年运营亏损1,470万美元,同比改善10%(2024年为1,650万

    03-27 12:16

  • CytoSorbents Q4 Adj. EPS $(0.07) Misses $(0.05) Estimate, Sales $9.234M Miss $9.587M Estimate

    CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 50 percent increase over losses of $(0.14) per share from the same

    03-26 04:11

  • Earnings Scheduled For March 25, 2026

    Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...

    03-25 19:11

  • CytoSorbents Hosts ISICEM 2026 Symposium in Brussels

    CytoSorbents Hosts ISICEM 2026 Symposium in Brussels CytoSorbents attended the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels. The company hosted a featured symposium titled “Hemoadsorption as part of an individualized patient concept in Intensive Care - Key Le

    03-19 21:45

  • CytoSorbents Corporation updates financial calendar with upcoming earnings report and webcast

    CytoSorbents Corporation updates financial calendar with upcoming earnings report and webcast CytoSorbents Corporation (NASDAQ: CTSO) will report fourth quarter and full year 2025 financial results on Wednesday, March 25, 2026, with results released by the Company. Management will host a live presen

    03-05 20:02